Annexin Pharmaceuticals AB (ANNX) Stock Price & Analysis

2 Followers

ANNX Stock Chart & Stats

SEK 6.26-SEK 0.32(-4.86%)

At close: Nov 03 5:30 PM GMT+1

Day’s Range: SEK 6.26 - SEK 6.50
52-Week Range: SEK 6.26 - SEK 27.38
Previous Close: SEK 6.58
Volume: N/A
Average Volume (3M): 8,472
Market Cap: SEK 57.37M
Enterprise Value: SEK 51.98M
Total Cash (Recent Filing): SEK 14.44M
Total Debt (Recent Filing): SEK 0
Price to Earnings (P/E): ―
Beta: 0.83
Next Earnings: Feb 11, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

The absence of debt reduces bankruptcy pressure, interest obligations, and refinancing exposure while the company funds development. This gives management greater flexibility to allocate capital toward ANXV and regulatory work, although ongoing losses still make overall financial resilience dependent on available funding.

Focused Vascular-disease Strategy

A clearly defined focus on vascular injury and inflammation gives Annexin a coherent scientific strategy rather than a broad, unfocused discovery portfolio. Concentration in severe disease areas may help direct limited resources toward specific development milestones and regulatory objectives.

Lead Candidate With Multiple Indications

ANXV’s development across retinal vein occlusion and kidney-related conditions provides more than one potential application for the same core therapeutic asset. If development progresses, this indication breadth could support a broader commercial opportunity without requiring an entirely separate platform.

Bears Say

No Revenue

The absence of revenue confirms that Annexin remains pre-commercial and cannot yet fund operations through customer or product sales. This leaves future progress dependent on successful development, approvals, and eventual commercialization, extending the period before the business can demonstrate operating self-sufficiency.

Persistent Operating Losses

Large recurring losses indicate that development spending continues to materially exceed any operating income. With losses widening again in the latest TTM period after a 2025 improvement, profitability remains unestablished and the company has limited evidence that earnings can improve sustainably over the next several quarters.

Ongoing Cash Burn And Funding Need

Persistent negative operating and free cash flow means Annexin consumes cash while advancing its programs and has not developed an internal funding engine. The TTM burn increased again after improving in 2025, reinforcing the likelihood that external financing may remain necessary if revenue stays absent.

ANNX FAQ

What was Annexin Pharmaceuticals AB’s price range in the past 12 months?

Annexin Pharmaceuticals AB lowest stock price was kr 6.26 and its highest was kr 27.38 in the past 12 months.

What is Annexin Pharmaceuticals AB’s market cap?

Annexin Pharmaceuticals AB’s market cap is kr 57.37M.

When is Annexin Pharmaceuticals AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Annexin Pharmaceuticals AB’s earnings last quarter?

Annexin Pharmaceuticals AB released its earnings results on Oct 22, 2026. The company reported -kr 1.26 earnings per share for the quarter.

Is Annexin Pharmaceuticals AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Annexin Pharmaceuticals AB pay dividends?

Annexin Pharmaceuticals AB does not currently pay dividends.

What is Annexin Pharmaceuticals AB’s EPS estimate?

Annexin Pharmaceuticals AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Annexin Pharmaceuticals AB have?

Annexin Pharmaceuticals AB has 8,718,182 shares outstanding.

What happened to Annexin Pharmaceuticals AB’s price movement after its last earnings report?

Annexin Pharmaceuticals AB reported an EPS of -kr 1.26 in its last earnings report. Following the earnings report the stock price went down -6.459%.

Which hedge fund is a major shareholder of Annexin Pharmaceuticals AB?

Currently, no hedge funds are holding shares in SE:ANNX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description